Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

Detalles Bibliográficos
Autores principales: Piper-Vallillo, Andrew J., Halbert, Brian T., Rangachari, Deepa, Kobayashi, Susumu S., Costa, Daniel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305494/
https://www.ncbi.nlm.nih.gov/pubmed/33225315
http://dx.doi.org/10.1016/j.jtocrr.2020.100071
_version_ 1783548472961531904
author Piper-Vallillo, Andrew J.
Halbert, Brian T.
Rangachari, Deepa
Kobayashi, Susumu S.
Costa, Daniel B.
author_facet Piper-Vallillo, Andrew J.
Halbert, Brian T.
Rangachari, Deepa
Kobayashi, Susumu S.
Costa, Daniel B.
author_sort Piper-Vallillo, Andrew J.
collection PubMed
description
format Online
Article
Text
id pubmed-7305494
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73054942020-06-22 Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer Piper-Vallillo, Andrew J. Halbert, Brian T. Rangachari, Deepa Kobayashi, Susumu S. Costa, Daniel B. JTO Clin Res Rep Case Report Elsevier 2020-06-20 /pmc/articles/PMC7305494/ /pubmed/33225315 http://dx.doi.org/10.1016/j.jtocrr.2020.100071 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Piper-Vallillo, Andrew J.
Halbert, Brian T.
Rangachari, Deepa
Kobayashi, Susumu S.
Costa, Daniel B.
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
title Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
title_full Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
title_fullStr Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
title_full_unstemmed Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
title_short Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
title_sort acquired resistance to osimertinib plus savolitinib is mediated by met-d1228 and met-y1230 mutations in egfr-mutated met-amplified lung cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305494/
https://www.ncbi.nlm.nih.gov/pubmed/33225315
http://dx.doi.org/10.1016/j.jtocrr.2020.100071
work_keys_str_mv AT pipervallilloandrewj acquiredresistancetoosimertinibplussavolitinibismediatedbymetd1228andmety1230mutationsinegfrmutatedmetamplifiedlungcancer
AT halbertbriant acquiredresistancetoosimertinibplussavolitinibismediatedbymetd1228andmety1230mutationsinegfrmutatedmetamplifiedlungcancer
AT rangacharideepa acquiredresistancetoosimertinibplussavolitinibismediatedbymetd1228andmety1230mutationsinegfrmutatedmetamplifiedlungcancer
AT kobayashisusumus acquiredresistancetoosimertinibplussavolitinibismediatedbymetd1228andmety1230mutationsinegfrmutatedmetamplifiedlungcancer
AT costadanielb acquiredresistancetoosimertinibplussavolitinibismediatedbymetd1228andmety1230mutationsinegfrmutatedmetamplifiedlungcancer

Ejemplares similares